Page 164 - Read Online

Singh-Ranger. Mini-invasive Surg 2018;2:39 I http://dx.doi.org/10.20517/2574-1225.2018.23 Page 5 of 5

effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S-64S.
19. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical
selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
20. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
N Engl J Med 2012;367:1596-606.
21. Langley RE, Rothwell PM. Potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol 2013;10:8-10.
22. Jung YR, Kim EJ, Choi HJ, Park JJ, Kim HS, et al. Aspirin targets SIRT1 and AMPK to induce senescence of colorectal carcinoma
cells. Mol Pharmacol 2015;88:708-19.
23. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191
patients enrolled in 50 randomized controlled trials. Am J Hematol 2004;75:40-7.
24. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004;328:477-9.
25. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al. Profile and prevalence of aspirin resistance in patients with
cardiovascular disease. Am J Cardiol 2001;88:230-5.
26. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-13.
27. Gibaldi M, Grundhofer B. Bioavailability of aspirin from commercial suppositories. J Pharm Sci 1975;64:1064-6.
28. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional
chromatography. J Pharm Biomed Anal 1999;21:383-92.
29. Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, et al. Bioavailability of aspirin and salicylamide following oral co-
administration in human volunteers. Can J Physiol Pharmacol 1991;69:1436-42.
30. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, et al. Inhibition of platelet aggregation by aspirin progressively
decreases in long term treated patients. J Am Coll Cardiol 2004;43:979-84.
31. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al. Profile and prevalence of aspirin resistance in patients with
cardiovascular disease. Am J Cardiol 2001;88:230-5.
32. Tran HV, Waring ME, McManus DD, Erskine N, Do VTH, et al. Underuse of Effective Cardiac Medications Among Women, Middle-
Aged Adults, and Racial/Ethnic Minorities With Coronary Artery Disease (from the National Health and Nutrition Examination Survey
2005 to 2014). Am J Cardiol 2017;120:1223-9.
33. Singh Ranger G, McKinley-Brown C. Aspirin utilization, compliance and prevention of colorectal cancer - A single centre perspective.
Available from: https://academic.oup.com/annonc/article/27/suppl_6/1342P/2800238. [Last accessed on 19 Nov 2018]